Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID

NewsGuard 100/100 Score
Apr 7 2010

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.  

"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"

Poster presenter:  Derrick Crook, M.D.

Saturday, April 10, 2010 3:30pm–4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2401

"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"

Poster presenter:  Mark A. Miller, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2394

Source:

Optimer Pharmaceuticals, Inc.

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Lancet Commission predicts sharp increase in global prostate cancer cases
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
New urine-based test improves identification of high-grade prostate cancer
LabVantage celebrates customer success with record number of software deployments in FY 2024
Supply chain assessment and management, optimizing pharmaceutical supply chains
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk